Novartis Overview
Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz). These three divisions are supported by the research organization, the Novartis Institutes for BioMedical Research, and a centralized services group, Novartis Business Services, to facilitate collaboration across the divisions and drive efficiency and productivity gains. In Israel, in addition to the marketing department, Novartis has a division engaged in medical research and development of new drugs and a wide range of clinical research activities. In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, a company that develops devices for ophthalmologic applications and glaucoma surgery. Since its acquisition, Optonol operates as a subsidiary of the company. Novartis also operates in Israel a Cyber Security research center. Novartis is also present in Israel, through its innovation center BIOME.
Latest News
growth-positive
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche has announced its acquisition of 89bio, a clinical-stage biopharmaceutical company, for $3.5 billion. This strategic move aims to enhance Roches portfolio in cardiovascular, renal, and metabolic diseases by adding 89bios promising phase III candidate, pegozafermin, to its pipeline. Pegozafermin is in late-stage development for treating metabolic dysfunction-associated steatohepatitis (MASH) in fibrotic and cirrhotic patients. The acquisition, approved by both companies boards, is expected to close in the fourth quarter of 2025. The deal includes a contingent value right (CVR) for 89bio stockholders, potentially increasing the total consideration by up to $1 billion if certain sales milestones are met. This acquisition is seen as a positive growth opportunity for Roche, aligning with its strategic focus on lucrative therapeutic areas.
Acquisition
growth-positive
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
growth-positive
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.
Product Stage
growth-positive
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
The article discusses the positive performance of U.S. stock indices on July 17, 2025, driven by growth factors such as improved retail sales and decreased unemployment claims. Notably, Netflixs better-than-expected earnings results contributed to investor confidence and Wall Streets performance. The article advises investors to consider low-leverage stocks like Novartis, ResMed Inc., Wabtec, Elbit Systems, and Ingredion Inc. to mitigate risks associated with market volatility. It explains the concept of leverage and its implications for financial risk, emphasizing the importance of selecting companies with lower debt-to-equity ratios for safer investments.
Team Members
1
Employees: 51-200
Web & Social Links
| Website | www.novartis.com |
Locations
Totseret ha-Arets Street 6, Tel Aviv-Yafo, Israel
Neve Ilan, Israel
Basel, Switzerland
Photos & Videos
No files yet
